Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects
Retrieved on:
Saturday, November 4, 2023
Society for Immunotherapy of Cancer, Mitochondrion, Immunogenic cell death, ICD, Bax, Northern blot, Doctor of Philosophy, Phosphorylation, Bcl-2, SITC, Cancer immunotherapy, Immunotherapy, Reactive oxygen species, ISR, Research and development, Cancer, Flow cytometry, Annual general meeting, Weill Cornell Medicine, Lung cancer, Endoplasmic reticulum, Society, Therapy, Patient, Cytosol, DNA, Vaccine, Platinum, Research
NEW YORK, Nov. 4, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a Phase 2 stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, and its ability to induce immunogenic cell death (ICD) in cancer cells. Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism. The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.
Key Points:
- Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism.
- The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.
- PT-112 effects on mitochondria included increases in mitochondrial mass and reactive oxygen species, changes in membrane polarization, and the release of mitochondrial DNA into the cytosol, a potent immunogenic signal.
- For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com .